Clinical Trials
8 trialsNCT01990209 2022-06-30
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01816048 2019-12-09
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
University of Wisconsin, Madison
Phase 2 Terminated
NCT02101684 2018-03-05
Greko II
Grupo EspaƱol de Tumores HuƩrfanos e Infrecuentes
Phase 2 Terminated
NCT01866423 2017-08-31
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT03211052 2017-07-07
NEPTUNE
Queen Mary University of London
Phase 2 Terminated
NCT01658527 2016-06-10
TAK-700 in Castration Resistant Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT01549951 2016-06-01
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT01046916 2016-04-04
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
Millennium Pharmaceuticals, Inc.
Phase 2 Completed